Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News Management Comments

Iovance Biotherapeutics (IOVA) Reports In-Line Q4 EPSFebruary 27, 2019 4:57 PM Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical CancerFebruary 26, 2019 7:01 AM